This “Spasticity - Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Spasticity pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Spasticity: Understanding
Spasticity: Overview
Spasticity is a motor disorder characterized by a velocity-dependent increase in muscle tone, often referred to as muscle tightness or stiffness. It can range from mild to severe, potentially interfering with mobility, daily activities, hygiene, and comfort, and may lead to complications like contractures, pressure ulcers, or joint dislocation. Despite its challenges, spasticity can offer functional benefits for some patients by aiding in weight-bearing and mobility, which may help improve circulation, reduce the risk of osteoporosis, and support mental well-being. Management typically involves a combination of physical therapy, pharmacologic interventions, and sometimes surgical procedures. Accurate assessment of the severity and impact of spasticity is crucial to determine the most effective treatment approach. Early intervention can help prevent long-term complications and improve quality of life. A patient-centered strategy that balances symptom control with preserved function is key in optimizing outcomes.
Signs and symptoms of spasticity include increased muscle tone, muscle stiffness or tightness, and exaggerated reflexes such as hyperactive tendon jerks. Patients may experience muscle spasms, clonus (involuntary, rhythmic muscle contractions), and difficulty with voluntary movements. Spasticity can lead to joint immobility, muscle fatigue, and pain, often interfering with activities of daily living such as walking, dressing, or maintaining hygiene. In severe cases, it may result in abnormal postures, contractures, or difficulty speaking and swallowing, depending on the muscles involved. The severity and presentation can vary widely based on the underlying neurological condition and the affected muscle groups.
The pathophysiology of spasticity involves damage to the upper motor neurons in the central nervous system, which disrupts the balance between excitatory and inhibitory signals that regulate muscle tone. This damage leads to reduced inhibition of spinal reflexes, resulting in hyperexcitability of the stretch reflex arc. As a consequence, muscles become overly responsive to stretch, especially at higher velocities, causing increased muscle tone and exaggerated tendon reflexes. Key mechanisms include altered synaptic activity, enhanced excitatory neurotransmission, and changes in muscle and connective tissue properties, all contributing to the sustained muscle stiffness and spasms characteristic of spasticity.
The treatment of spasticity follows a stepwise approach, starting with conservative measures and progressing to invasive options based on the patient's condition and goals. Initial management includes addressing noxious stimuli and using physical modalities such as stretching, splinting, and electrical stimulation. Pharmacologic treatments like baclofen, tizanidine, dantrolene, and diazepam help reduce tone and pain but may not improve function significantly. For focal spasticity, options like nerve blocks, chemical neurolysis, and botulinum toxin injections offer targeted relief. In severe or generalized cases, intrathecal baclofen pumps or surgical interventions may be considered to improve quality of life and functionality.
"Spasticity - Pipeline Insight, 2025" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Spasticity pipeline landscape is provided which includes the disease overview and Spasticity treatment guidelines. The assessment part of the report embraces, in depth Spasticity commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Spasticity collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Spasticity R&D. The therapies under development are focused on novel approaches to treat/improve Spasticity.
Spasticity Emerging Drugs Chapters
This segment of the Spasticity report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Spasticity Emerging Drugs
Spasticity: Therapeutic Assessment
This segment of the report provides insights about the different Spasticity drugs segregated based on following parameters that define the scope of the report.
Major Players in Spasticity
The report covers around 12+ products under different phases of clinical development, like:
Spasticity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as:
Products have been categorized under various Molecule types, such as:
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Spasticity: Pipeline Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Spasticity therapeutic drugs key players involved in developing key drugs.
Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Spasticity drugs.
Spasticity Report Insights
Current Treatment Scenario and Emerging Therapies:
This product will be delivered within 2 business days.
Spasticity: Understanding
Spasticity: Overview
Spasticity is a motor disorder characterized by a velocity-dependent increase in muscle tone, often referred to as muscle tightness or stiffness. It can range from mild to severe, potentially interfering with mobility, daily activities, hygiene, and comfort, and may lead to complications like contractures, pressure ulcers, or joint dislocation. Despite its challenges, spasticity can offer functional benefits for some patients by aiding in weight-bearing and mobility, which may help improve circulation, reduce the risk of osteoporosis, and support mental well-being. Management typically involves a combination of physical therapy, pharmacologic interventions, and sometimes surgical procedures. Accurate assessment of the severity and impact of spasticity is crucial to determine the most effective treatment approach. Early intervention can help prevent long-term complications and improve quality of life. A patient-centered strategy that balances symptom control with preserved function is key in optimizing outcomes.
Signs and symptoms of spasticity include increased muscle tone, muscle stiffness or tightness, and exaggerated reflexes such as hyperactive tendon jerks. Patients may experience muscle spasms, clonus (involuntary, rhythmic muscle contractions), and difficulty with voluntary movements. Spasticity can lead to joint immobility, muscle fatigue, and pain, often interfering with activities of daily living such as walking, dressing, or maintaining hygiene. In severe cases, it may result in abnormal postures, contractures, or difficulty speaking and swallowing, depending on the muscles involved. The severity and presentation can vary widely based on the underlying neurological condition and the affected muscle groups.
The pathophysiology of spasticity involves damage to the upper motor neurons in the central nervous system, which disrupts the balance between excitatory and inhibitory signals that regulate muscle tone. This damage leads to reduced inhibition of spinal reflexes, resulting in hyperexcitability of the stretch reflex arc. As a consequence, muscles become overly responsive to stretch, especially at higher velocities, causing increased muscle tone and exaggerated tendon reflexes. Key mechanisms include altered synaptic activity, enhanced excitatory neurotransmission, and changes in muscle and connective tissue properties, all contributing to the sustained muscle stiffness and spasms characteristic of spasticity.
The treatment of spasticity follows a stepwise approach, starting with conservative measures and progressing to invasive options based on the patient's condition and goals. Initial management includes addressing noxious stimuli and using physical modalities such as stretching, splinting, and electrical stimulation. Pharmacologic treatments like baclofen, tizanidine, dantrolene, and diazepam help reduce tone and pain but may not improve function significantly. For focal spasticity, options like nerve blocks, chemical neurolysis, and botulinum toxin injections offer targeted relief. In severe or generalized cases, intrathecal baclofen pumps or surgical interventions may be considered to improve quality of life and functionality.
"Spasticity - Pipeline Insight, 2025" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Spasticity pipeline landscape is provided which includes the disease overview and Spasticity treatment guidelines. The assessment part of the report embraces, in depth Spasticity commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Spasticity collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Spasticity R&D. The therapies under development are focused on novel approaches to treat/improve Spasticity.
Spasticity Emerging Drugs Chapters
This segment of the Spasticity report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Spasticity Emerging Drugs
MTR-601: Motric Bio
MTR-601, represents a potential first-in-class antispastic therapy with a unique mechanism of action that directly targets the contractile protein - myosin 2 - in fast-twitch skeletal muscle. As an oral, selective inhibitor, MTR-601 is designed to offer a non-invasive approach for the treatment of cervical dystonia, targeting fast-twitch muscle fibers with the potential to decrease stiffness and potentially improve physical function. MTR-601 on a robust body of preclinical data that demonstrates initial activity in selectively relaxing fast-twitch skeletal muscle subtypes. In a preclinical model, MTR-601 was also shown to improve gait function in spastic cerebral palsy. Currently, the drug is in Phase II stage of its development for the treatment of Spasticity.IPN10200: Ipsen
IPN10200 is a long-acting botulinum neurotoxin candidate developed by Ipsen for the treatment of upper limb spasticity. Engineered for extended duration of effect, it aims to provide sustained relief from muscle hyperactivity by inhibiting acetylcholine release at neuromuscular junctions. As a targeted neurotoxin therapy, IPN10200 is designed to reduce muscle tone more consistently over time, potentially reducing injection frequency and improving patient convenience. Its development reflects Ipsen’s strategic focus on neuroscience and its commitment to advancing innovative therapeutic options in spasticity management. Currently, the drug is in Phase I/II stage of its development for the treatment of Spasticity.Spasticity: Therapeutic Assessment
This segment of the report provides insights about the different Spasticity drugs segregated based on following parameters that define the scope of the report.
Major Players in Spasticity
- There are approx. 10+ key companies which are developing the therapies for Spasticity. The companies which have their Spasticity drug candidates in the most advanced stage, i.e. Phase II include, Motric Bio.
The report covers around 12+ products under different phases of clinical development, like:
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of:
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Spasticity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as:
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Products have been categorized under various Molecule types, such as:
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Spasticity: Pipeline Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Spasticity therapeutic drugs key players involved in developing key drugs.
Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Spasticity drugs.
Spasticity Report Insights
- Spasticity Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Spasticity drugs?
- How many Spasticity drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Spasticity?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Spasticity therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Spasticity and their status?
- What are the key designations that have been granted to the emerging drugs?
- Motric Bio
- Ipsen
- Saol Therapeutics Inc
- Elpida Therapeutics SPC
- Celgene
- Tris Pharma, Inc.
- MTR-601
- IPN10200
- SL-1002
- MELPIDA
- BMS-986368
- TRN-213
This product will be delivered within 2 business days.
Table of Contents
IntroductionExecutive SummarySpasticity - Analytical PerspectiveSpasticity Key CompaniesSpasticity Key ProductsSpasticity - Unmet NeedsSpasticity - Market Drivers and BarriersSpasticity - Future Perspectives and ConclusionSpasticity Analyst ViewsSpasticity Key CompaniesAppendix
Spasticity: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
Drug Name: Company Name
Mid Stage Products (Phase II)
MTR-601: Motric Bio
Early Stage Products (Phase I/II)
IPN10200: Ipsen
Preclinical and Discovery Stage Products
Drug Name: Company Name
Inactive Products
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Motric Bio
- Ipsen
- Saol Therapeutics Inc
- Elpida Therapeutics SPC
- Celgene
- Tris Pharma, Inc.
